tyrosine kinase inhibitor

You have access
Impact of Post-progression Survival on Outcomes of Lenvatinib Treatment for Unresectable Hepatocellular Carcinoma: A Systematic Review and Retrospective Cohort Study
KAZUTO TAJIRI, YOSHIHARU TOKIMITSU, KENGO KAWAI, YUCHI MOTOFUJI, EIJI SHINNO, YOSHIRO KASHII, NOZOMU MURAISHI, AIKO MURAYAMA, YUKA HAYASHI, MASAMI MINEMURA, TERUMI TAKAHARA, YUKIHIRO SHIMIZU and ICHIRO YASUDA

Anticancer Research December 2022, 42 (12) 6007-6018; DOI: https://doi.org/10.21873/anticanres.16112
You have access
Efficacy and Safety of Lenvatinib for Patients With Advanced Hepatocellular Carcinoma: A Retrospective, Real-world Study Conducted in Japan
NAOTAKA SHIMOZATO, TADASHI NAMISAKI, AKIHIRO OKANO, MASAYA OHANA, DAISUKE KINOSHITA, TOSHIHIKO KAWASAKI, YOSUKE AIHARA, TOSHIYA NAKATANI, HIROKI KINOSHITA, TATSUICHI ANN, KO SAITO, MOTOYUKI YOSHIDA and HITOSHI YOSHIJI

Anticancer Research January 2022, 42 (1) 173-183; DOI: https://doi.org/10.21873/anticanres.15471
You have access
Real-world Outcomes of Tyrosine Kinase Inhibitors Immediately After Immune Checkpoint Inhibitors in Renal Cell Carcinoma
TAIGO KATO, AKIRA NAGAHARA, NORIHIKO KAWAMURA, WATARU NAKATA, TETSUJI SODA, KYOSUKE MATSUZAKI, KOJI HATANO, ATSUNARI KAWASHIMA, TAKESHI UJIKE, RYOICHI IMAMURA, KENSAKU NISHIMURA, SHINGO TAKADA, MASAO TSUJIHATA, SEIJI YAMAGUCHI, TETSUYA TAKAO, YASUTOMO NAKAI, MASASHI NAKAYAMA, NORIO NONOMURA and MOTOHIDE UEMURA

Anticancer Research November 2021, 41 (11) 5811-5816; DOI: https://doi.org/10.21873/anticanres.15398
You have access
Targeted Therapy Followed by Cytotoxic Chemotherapy in Preoperative Patients With Locally Advanced Lung Adenocarcinoma
MASAYA AOKI, KAZUHIRO UEDA, TADASHI UMEHARA, GO KAMIMURA, TAKUYA TOKUNAGA, AYA HARADA-TAKEDA, KOKI MAEDA, TOSHIYUKI NAGATA, NAOYA YOKOMAKURA, KOTA KARIATSUMARI, YUTO NONAKA, NOBUHIRO IMAMURA, SHOICHIRO MORIZONO and MASAMI SATO

Anticancer Research May 2020, 40 (5) 2911-2916; DOI: https://doi.org/10.21873/anticanres.14268
You have access
Efficacy of Afatinib and Lapatinib Against HER2 Gene-amplified Trastuzumab-sensitive and -resistant Human Gastric Cancer Cells
SUSUMU NAKATA, MITSUGU FUJITA and HAYAO NAKANISHI

Anticancer Research November 2019, 39 (11) 5927-5932; DOI: https://doi.org/10.21873/anticanres.13797
You have access
Antiproliferative Effect of Lenvatinib on Human Liver Cancer Cell Lines In Vitro and In Vivo
SACHIKO OGASAWARA, YUTARO MIHARA, REIICHIRO KONDO, HIRONORI KUSANO, JUN AKIBA and HIROHISA YANO

Anticancer Research November 2019, 39 (11) 5973-5982; DOI: https://doi.org/10.21873/anticanres.13802
You have access
Neoadjuvant Tyrosine Kinase Inhibition in Locally-advanced Non-small Cell Lung Cancer: Two Cases and a Brief Literature Review
ANISH B. PARIKH, LINDSAY HAMMONS and JORGE E. GOMEZ

Anticancer Research February 2019, 39 (2) 897-902; DOI: https://doi.org/10.21873/anticanres.13191
You have access
Prognostic Significance of Pancreatic Metastases from Renal Cell Carcinoma in Patients Treated with Tyrosine Kinase Inhibitors
PAWEL CHROM, RAFAL STEC, LUBOMIR BODNAR and CEZARY SZCZYLIK

Anticancer Research January 2018, 38 (1) 359-365;
You have access
Identification of MicroRNAs Involved in Resistance to Sunitinib in Renal Cell Carcinoma Cells
NORIYA YAMAGUCHI, MITSUHIKO OSAKI, KUNISHIGE ONUMA, TETSUYA YUMIOKA, HIDETO IWAMOTO, TAKEHIRO SEJIMA, HIROYUKI KUGOH, ATSUSHI TAKENAKA and FUTOSHI OKADA

Anticancer Research June 2017, 37 (6) 2985-2992;
You have access
Increased HGF Expression Induces Resistance to c-MET Tyrosine Kinase Inhibitors in Gastric Cancer
SO YEONG AHN, JIN KIM, MIN A KIM, JIWOON CHOI and WOO HO KIM

Anticancer Research March 2017, 37 (3) 1127-1138;

Main menu

User menu

Search

tyrosine kinase inhibitor

Pages